ESG

ESG

ESG

ESG

GWOXI is dedicated to advancing stem cell innovation while upholding sustainability. With over 120 patents and multiple stem cell drugs in clinical trials, we balance medical breakthroughs with social and environmental responsibility. Our efforts span green manufacturing, academic-industry collaboration, support for vulnerable groups, and strict corporate governance, ensuring that innovation, responsibility, and excellence drive both scientific progress and positive social impact.

 

Press Releases

Press Releases
NEWS
  • /userfiles/images/news/20260818093325651.jpg
    18
    2026
    08
    Media
    Gwo Xi’s GXNPC1® Receives TFDA Approval for Phase III Clinical Trial to Address Chronic Stroke-Related Disability

  • /userfiles/images/news/common/20250729061912582.jpg
    20
    2025
    11
    Press Releases
    Gwo Xi Stem Cell Files Drug Master File (DMF) with FDA, Integrating into the Global Regenerative Medicine Industry Chain

  • /userfiles/images/news/251022/20251022090426346.jpg
    22
    2025
    10
    Press Releases
    Gwo Xi Stem Cell’s Diabetes Cell Therapy Product GXIPC1® Receives Phase I Trial Results Approval from Vietnam’s MOH